CIAM
IOVA icon

Caitong International Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Caitong International Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.8K Sell
7,407
-118,639
-94% -$451K ﹤0.01% 853
2026
Q1 		$442K Buy
126,046
+78,769
+167% +$252K 0.08% 216
2025
Q4 		$129K Buy
47,277
+41,047
+659% +$95K 0.03% 331
2025
Q3 		$13.5K Sell
6,230
-4,222
-40% -$9.97K 0.01% 908
2025
Q2 		$18K Buy
10,452
+10,284
+6,121% +$25.6K 0.01% 529
2025
Q1 		$559 Sell
168
-23,963
-99% -$124K ﹤0.01% 1737
2024
Q4 		$179K Buy
+24,131
New +$224K 0.17% 106

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Caitong International Asset Management's IOVA Position: Q2 2026 in Review

Caitong International Asset Management reduced its Iovance Biotherapeutics (IOVA) stake by 94% in Q2 2026, selling an estimated $451K and leaving 7,407 shares worth $30.8K. The position accounts for ﹤0.01% of the portfolio, ranked #853.

Caitong International Asset Management first reported a position in IOVA in Q4 2024 and has held it in 7 quarters since. The position peaked at $442K in Q1 2026. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Caitong International Asset Management held 7,407 shares of Iovance Biotherapeutics worth $30.8K as of Q2 2026.
  • Caitong International Asset Management sold 118,639 Iovance Biotherapeutics shares in Q2 2026, an estimated $451K.
  • Iovance Biotherapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #853 holding.
  • Caitong International Asset Management first reported a position in Iovance Biotherapeutics in Q4 2024 and has held it in 7 quarters since.
  • Caitong International Asset Management's Iovance Biotherapeutics position peaked at $442K in Q1 2026.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.